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Oxyntomodulin is a peptide isolated from porcine intestine which consists of the whole glucagon sequence 
extended at its C-terminal part by a basic octapeptide. The analogue (Nle-27)-oxyntomodulin of the human 
sequence has been synthesized by solid-phase peptide synthesis, purified by HPLC and identified. Its biologi- 
cal activities are the same as those of the natural hormone. 
Gastric acid secretion ~xyn~omodul~n Sound-ph~e peptide synthesis 
1. INTRODUCTION 
Oxyntomodulin, a peptide of 37 amino acid 
residues, has been isolated from porcine jejuno- 
ileum [l]. This peptide consists of the whole 
glucagon molecule (residues l-29) extended at its 
C-terminal end by an octapeptide [2] of sequence 
Lys-Arg-Asn-Lys-Asn-an-Ile-~a (fig. 1). Recent- 
ly, the amino acid sequence of human oxyn- 
tomodulin has been determined from the human 
preproglucagon gene [3]. It only differs from the 
pig sequence by a single replacement in the C- 
terminal octapeptide, an arginine replacing Lys-33. 
Glucagon and ox~tom~ulin showed different 
biological activities: on cyclic AMP accumulation 
in rat liver plasma membranes oxyntomodulin was 
-10% as potent as glucagon, but with the same ef- 
ficacy [2]. In contrast, oxyntomodulin was 
20-times more potent than glucagon in stimulating 
cyclic AMP accumulation in acid-secreting oxyntic 
glands isolated from the rat gastric mucosa [4]. 
Similarly, oxyntomodulin was lO-20-times more 
potent than glucagon in inhibiting pentagastrin- 
induced acid secretion in the anaesthetized rat [S]. 
These original characteristics of the molecule are 
related to the presence of an oxyntomodulin- 
specific binding site in the rat oxyntic glands (61. 
The C-terminal octapeptide of oxyntomodulin 
which differentiates oxyntomodulin from gluca- 
gon, of either the pig or human sequence, was 
shown to inhibit pentagastrin-induced acid secre- 
tion in ~aesth~~ed and conscious rats with the 
same efficacy as oxyntomodulin but with a lower 
potency (HO-fold) [7-g]. The affinity of oxyn- 
tomodulin for antibodies directed against the C- 
terminal sequence of glucagon was -1% that of 
glucagon [2]. The analogue (Nle-27)-oxynto- 
mod&n of the human (and rat) sequence, in which 
the Met-27 of the natural hormone has been 
replaced by a norleucine in order to overcome the 
problems encountered with methionine, was 
produced by solid-phase synthesis. The replace- 
ment of methionine by norleucine has been shown 
in many cases not to influence the biological ac- 
tivities of the analogues [lO-121. 
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(a) His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg- 
20 29 30 
Arg-Ala -Gin -Asp-Phe-Val - Gln -Trp - Leu -Met-Asn -Thr - Lys- Arg - Asn - 
37 
Lys- Asn- Asn-Ile -Ala 
1 IO 
( b) HIS -Ser-Glu-Gly-Thr -Phe-Thr -Ser -Asp -Tyr-Ser -Lys -Tyr -Leu -Asp -Ser-Arg- 
20 29 30 
Arg-Ala -Glu -Asp-Phe-Val - Gln -Trp - Leu -N&-Asn -Thr - Lys -Arg - Asn- 
37 
Arg-Asn-Asn-Ile - Ala 
Fig. 1. Amino acid sequence of pig oxyntomodulin (a) and the synthetic human (Nle-27)-oxyntomodulin analogue (b). 
Differences in amino acid residues are underlined. Amino acids of the glucagon sequence are in bold letters. 
2. MATERIALS AND METHODS 
2.1. Synthesis of human (Nle-27)-oxyntomoduiin 
analogue 
Solid-phase synthesis of (Nle-27)-oxyntomodu- 
lin was performed on the conventional support 
Boc-Ala-GCH2C& resin (Merrifield resin), 
prepared by the caesium salt procedure [13]. The 
extent of coupling was monitored by the method of 
Gisin [14] after acidolysis of the t-butyloxycar- 
bony1 (Boc) protecting group and gave a substitu- 
tion of 0.35 mmol/g resin. Boc protection was 
adopted for N_(y protection of amino acids used in 
this synthesis. Side chain protecting groups were: 
p-toluenesulphonyl for the guanidino of arginines; 
2-chlorobenzyloxycarbonyl for the f-NH2 of 
lysines; 4-cyclopentyl ester for the ,&COOH of 
aspartic acids; p-chlorobenzyl ether for the hy- 
droxyl groups of serines and threonines; 2,6-di- 
chlorobenzyl ether for tyrosines; formyl for the in- 
dole nucleus of tryptophan; and Boc for the im- 
idazole of the N-terminal histidine. The N-cy Boc 
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protecting group was removed at each step by a 
mixture of trifluoroacetic acid in 50% dichloro- 
methane. Coupling was usually performed using 
the BOP reagent [15] or the active ester method @- 
nitrophenyl esters) in the case of asparagines and 
glutamines and subsequent catalysis by l-hydroxy- 
benzotriazole [ 161. The progression of synthesis 
was monitored by a qualitative ninhydrin assay 
[ 171 and by fluorescamine [181 at the end of each 
coupling step. After the last coupling with bis-Boc- 
histidine and partial deblocking with trifluoro- 
acetic acid, total deprotection and liberation of the 
peptide from the resin were performed by the low- 
high HF procedure [19] in a mixture of dimethyl 
sulphide/HF/p-cresol/p-thiocresol (65:25:5:5) 
for 2 h at 0°C and then for 1 h at 0°C in a mixture 
of p-cresol/p-thiocresol/HF (5 : 5 : 95). 
2.2. Purification of the peptide 
The crude peptide (fig.2) was purified by HPLC, 
on a /cBondapak Cis column using a gradient of 
0.1% TFA in water/acetonitrile containing 0.05% 
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Fig.2. HPLC profile of crude (Nle-27)-oxyntomodulin. 
/tBondapak Crs column (lO,#m); gradient, O-SO% 
solvent B in 50 min (solvent A: water/t~fluoroacetic 
acid, 0.1%; solvent B: acetonitrile/ethyl acetate, 
0.05~0); flow rate, 1.5 ml/mm; detection, UV (280 nm). 
ethyl acetate [l]. The apparatus consisted of two 
solvent delivery systems (model 6000 A) controlled 
by a solvent programmer (model 720), a U6K in- 
jector and two UV detectors (model 441) operated 
at 280 and 214 nm, respectively. These instruments 
were from Waters (France). UV spectra 
(2~3~ nm) were directly obtained from the 
chromatographic peaks using an HP 8450 diode 
array spectrophotometer (Hewlett-Packard, 
USA). The purity of (Nle-27)-oxyntomodulin was 
checked by HPLC on a pBondapak CN column 
and apBondapak Crs column (fig.3). 
2.3. Identificution of the peptide 
Amino acid analysis was performed after acid 
hydrolysis of the synthetic purified material (6 N 
HCI, 18 h, 108”C), in the presence of phenol 
(0.1 To) and 2-mercaptoethanol (0.05%) [20], ac- 
cording to Fleury and Ashley 1211 and gave the ex- 
pected values for each amino acid residue: Asp 6.9 
(7), Glu 3.3 (3), Ser 3.1 (4), His 0.8 (l), Gly 1 (l), 
Thr 3 (3), Arg 2.6 (3), Ala 1.6 (2), Tyr 1.7 (2), Val 
0.9 (I), Phe 2.1 (2), Ile 1.1 (l), Leu 2.8 (3), Lys 3.2 
(3). 
The synthetic material was compared by HPLC 
with natural pig oxyntomodulin on a pBondapak 
Crs and apBondapak CN column, using the condi- 
tions of purification. Both showed almost the same 
retention time. 
The UV spectra of the synthetic (Nle-27)- 
cl3 
t 
Fig.3. (a) HPLC profile of pure (Nle-U)- 
oxyntomodulin. FBondapak Crs column (lo/cm; 
Waters); gradient, O-50% solvent B in 50 min (solvent 
A: water/trifluoroacetic acid, 0.1%; solvent B: 
acetonitrile/e~yl acetate, 0.05?70); flow rate, 
1.5 mllmin; detection, UV (280 nm). (b) HPLC profile 
of pure (Nle-27)oxyntomodulin. pBondapak CN 
column (Waters); gradient, 1040% solvent B in 20 min 
(solvent A: water/trifluoroacetic acid, 0.1%; solvent B: 
acetonitrile/ethyl acetate, 0.05ora); flow rate, 
1.5 ml/min; detection, UV (280 nm). 
oxyntomodulin and the natural compound were 
identical. Only a small difference could be seen 
between 210 and 230 nm which may be due to the 
influence of the norleucine and arginine residues of 
the synthetic material that respectively replace 
methionine and lysine. 
Pure (Nle-27)oxyntomodulin and glucagon 
were hydrolyzed with the enzyme Armillaria 
meileu neutral proteinase, which resulted in a com- 
plete cleavage at the amino group of the lysine 
183 
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residues [17]. Both peptides resulted in different 
fragments which were identified by HPLC and 
their UV spectra. Glucagon led to peptides l-11 
and 12-29; (Nle-27)-oxyntomodulin led to pep- 
tides l-l 1 (identical to the l-l 1 fragment ob- 
tained from glucagon), 12-29 and 30-37. The pep- 
tide 30-37 was similar to the octapeptide Lys-Arg- 
Asn-Arg-Asn-Asn-Ile-Ala formed by solid-phase 
synthesis and by the conventional technique in 
solution in our laboratory. Peptides 12-29 pro- 
duced from the hydrolysis of glucagon and of the 
synthetic material were slightly different, owing to 
the difference in the Nle/Met residues. 
3. BIOLOGICAL ACTIVITIES 
The synthetic peptide showed the same 
biological activity as the natural hormone. On a 
molar basis, natural pig oxyntomodulin and the 
human (Nle-27)-oxyntomodulin analogue possess 
the same affinity as pancreatic glucagon (G29) for 
an anti-glucagon antibody prepared in our 
laboratory [2] (fig.4). With respect to the inhibi- 
tion of binding of “‘1-glucagon to rat liver plasma 
membranes as described in [l], both peptides 
oJ, , , , , , , , , , 
06 25 10 40 160 
Pept~des (fmol /tube) 
Fig.4. Effects of glucagon (G37) (o), synthetic (Nle-27)- 
oxyntomodulin analogue (0) and natural pig 
oxyntomodulin (g37) (A) on the binding of **‘I-glucagon 
to an anti-glucagon antibody (666-6) produced in our 
laboratory. 
oJr , , , , , , , , , 
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Fig.5. Effects of glucagon (G29) (o), synthetic (Nle-27)- 
oxyntomodulin analogue (0) and pig oxyntomodulin 
(A) on the binding of ‘2SI-glucagon to rat liver plasma 
membranes. 
behave similarly (fig.5). On the inhibition of 
pentagastrin-stimulated acid secretion in the con- 
scious rat [9], both the synthetic and the natural 
material gave the 
(100 pmol of each 
inhibition). 
same extent of inhibition 
peptide gave approx. 50% 
4. CONCLUSION 
The synthesis of the (Nle-27)-oxyntomodulin 
analogue of the human sequence was performed by 
solid-phase peptide synthesis. The synthetic 
material was purified, characterized and its 
biological activities evaluated and compared to 
those of the natural peptide. As observed in many 
other examples, this synthesis confirms that the 
replacement of methionine by norleucine does not 
affect the biological activity of the hormone, but 
increases its stability particularly towards oxida- 
tion. However, from these preliminary results, 
apart from some minor differences, it seems that 
the substitution of Lys-33 (from the pig sequence) 
by arginine (human or rat sequence) does not have 
any influence on the biological responses. This 
synthesis, which allowed us to obtain significant 
amounts of the (Nle-27)-oxyntomodulin analogue, 
184 
Volume 200, number 1 FEBS LETTERS May 1986 
Cill permit us to investigate in further detail the 
biological activities and probable physiological 
role of this molecule. 
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